Micro Aftermath Archived

Le rétatrutide de LLY montre des résultats d'essais mitigés

Activité en déclin — le récit perd de sa pertinence.

Score
0,3
Vélocité
▲ 0,0
Articles
6
Sources
2

Chronologie des sentiments

Chronologie des événements

Avr 05, 2026
Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster” Bullish
Mar 28, 2026
1 Reason Eli Lilly Stock Is Still a Buy Neutral
Mar 22, 2026
Should You Buy Eli Lilly Stock Before April 10? Bullish
Mar 21, 2026
RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite … Neutral

Articles Liés

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster”

Yahoo Finance · Avr 05, 2026
Mixed

Should You Buy Eli Lilly Stock Before April 10?

Nasdaq · Mar 22, 2026
Mixed

Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial

Yahoo Finance · Mar 22, 2026
Bearish

RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results

Yahoo Finance · Mar 21, 2026
Mixed

Chronologie

Première observationMar 21, 2026
Dernière mise à jourMar 21, 2026